![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Baseline viral load thresholds predicting virological response to peginterferon alfa-2a/ribavirin in HCV G2 and G3 patients: PROPHESYS cohort sub-analysis
|
|
|
Reported by Jules Levin
APASL Liver Week
Singapore, June 6-10, 2013
Reported by Jules Levin
APASL Liver Week 2013; 6-10 June, Singapore
M.L. Shiffman,1 G. Parruti,2 P. Ferenci,3 M. Gschwantler,4 G. De Bartolomeo,5 N. Passariello,6 F. Caruntu,7 A. Horban,8 G. Lengyel,9 M. Schmitz,10 C. Golotta,11F. Tatsch12; on behalf of the PROPHESYS study group
1Liver Institute of Virginia, Richmond and Newport News, VA, USA; 2Infection Control Unit, Santo Spirito General Hospital, Pescara, Italy; 3Medical University of Vienna, Vienna, Austria; 44th Department of Internal Medicine, Wilhelminenspital, Vienna, Austria; 5Liver Unit - Internal Medicine, Ospedale F. Veneziale, Isernia, Italy; 6Department of Geriatrics and Metabolic Diseases, University of Naples, Naples, Italy; 7Institute for Infectious Diseases 'Matei Bals', Bucharest, Romania; 8Medical University Clinic of Infectious Diseases, Warsaw, Poland; 9Semmelweis University, 2nd Department of Medicine, Budapest, Hungary; 10IST GmbH, Mannheim, Germany; 11Roche SpA, Monza, Italy; 12F. Hoffmann-La Roche Ltd, Basel, Switzerland
![APASL1.gif](../images/061713/061713-1/APASL1.gif)
![APASL2.gif](../images/061713/061713-1/APASL2.gif)
![APASL3.gif](../images/061713/061713-1/APASL3.gif)
![APASL4.gif](../images/061713/061713-1/APASL4.gif)
![APASL5.gif](../images/061713/061713-1/APASL5.gif)
![APASL6.gif](../images/061713/061713-1/APASL6.gif)
![APASL7.gif](../images/061713/061713-1/APASL7.gif)
![APASL8.gif](../images/061713/061713-1/APASL8.gif)
![APASL9.gif](../images/061713/061713-1/APASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|